Artiva Biotherapeutics is a clinical-stage biotechnology company founded in 2019 as a spin-out of GC Cell and headquartered in San Diego, California. The company specialized in developing allogeneic, off-the-shelf, non-genetically modified natural killer (NK) cell therapies designed to enhance monoclonal antibody-mediated B-cell depletion in autoimmune diseases and oncology. On October 27, 2026, Artiva announced the permanent discontinuation of its lead candidate AlloNK (AB-101) following insufficient clinical response durability and two Grade 5 fatal events in its Phase 2a trial, enacted a 94% workforce reduction, and engaged Leerink Partners to evaluate strategic alternatives while managing approximately $319.1 million in cash and investments.
Expected completion of 94% workforce wind-down and evaluation of strategic alternatives with Leerink Partners
Artiva Biotherapeutics permanently discontinued development of its lead non-genetically modified allogeneic NK cell therapy AlloNK (AB-101) across all autoimmune indications—scrapping a planned Phase 3 rheumatoid arthritis trial—after longer-term Phase 2a clinical response durability fell short and two Grade 5 fatal events occurred (including fatal leukoencephalopathy linked to fludarabine lymphodepletion). Artiva slashed 94% of its ~115-person workforce and engaged Leerink Partners to explore strategic alternatives while holding ~$319.1M in cash.
Artiva Biotherapeutics halted all clinical development of its lead allogeneic NK cell therapy AlloNK (AB-101), scrapped a planned Phase 3 rheumatoid arthritis trial, and slashed 94% of its workforce after longer-term response durability fell short and two Grade 5 fatal events occurred.
President, Chief Executive Officer and Director
Chief Financial Officer and EVP, Corporate Development
No active job listings. Check back later.